AD_____

Award Number: DAMD17-02-1-0503

TITLE: ATM Mutations and the Development of Severe Radiation-Induced Morbidity Following Radiotherapy for Breast Cancer

PRINCIPAL INVESTIGATOR: Barry S. Rosenstein, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, NY 10029-6574

REPORT DATE: July 2005

TYPE OF REPORT: Annual

20060309 112

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Index approved scalar of the calculation of the index of the calculation of the calc		REPORT DOC		N PAGE		Form Approved OMB No. 0704-0188		
1. REPORT DATE (0D-MAY YYY) 2. REPORT TYPE 3. DATES COVERED (Prom fo) 4. TITLE AND SUBTITLE 1. Jul 2004 – 30 Jun 2005 3. DATES COVERAGE (Prom fo) 4. TITLE AND SUBTITLE 1. Jul 2004 – 30 Jun 2005 5. CONTRACT. NUMBER 5. ADTM Mutations and the Development of Severe Radiation-induced Morbidity 5. GRANT NUMBER Following Radiotherapy for Breast Cancer 5. GRANT NUMBER 5. AUTHOR(S) 5. FROGRAM ELEMENT NUMBER 8. BARY S. Rosenstein, Ph.D. 5. TASK NUMBER 6. AUTHOR(S) 5. TASK NUMBER 9. SPONSORING ORGANIZATION NAME(S) AND ADDRESS(ES) 3. PERFORMING ORGANIZATION REPORT Mount Sinal School of Medicine 8. PERFORMING ORGANIZATION REPORT New York, NY 10025-6374 10. SPONSORMONITOR'S ACRONYM(S) 11. SPONSORMONITOR'S ACRONYM(S) 11. SPONSORMONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late fissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An addinional objective is to determine the functional indice to the ATM gene for each genetic alteration identified and subsequent cellular radiosensitivity.	Public reporting burden for t data needed, and completin this burden to Department of 4302. Respondents should valid OMB control number.	his collection of information is esti g and reviewing this collection of i f Defense, Washington Headquar be aware that notwithstanding an PLEASE DO NOT RETURN YOU	mated to average 1 hour per res nformation. Send comments reg ers Services, Directorate for Info o ther provision of law, no perso R FORM TO THE ABOVE ADD	ponse, including the time for revie garding this burden estimate or an ormation Operations and Reports on shall be subject to any penalty to RESS.	wing instructions, searc y other aspect of this co 0704-0188), 1215 Jeffe or failing to comply with	hing existing data sources, gathering and maintaining the llection of information, including suggestions for reducing rson Davis Highway, Suite 1204, Arlington, VA 22202- a collection of information if it does not display a currently		
01-07-2005 1 Jul 2004 - 30 Jun 2005 ATTM EMB SUBTITE 1 Jul 2004 - 30 Jun 2005 ATM Mutations and the Development of Severe Radiation-Induced Morbidity 5. GRANT NUMBER Following Radiotherapy for Breast Cancer 5. GRANT NUMBER 6. AUTHOR(S) 5. GRANT NUMBER 7. PERFORMING Constant (International Constant) 5. GRANT NUMBER 6. AUTHOR(S) 5. GRANT NUMBER 7. PERFORMING CONSTANTION NAME(S) AND ADDRESS(ES) 5. FROGRAM ELEMENT NUMBER 7. PERFORMING CONSTRUCTION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Mount Sinal School of Medicine 8. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinal School of Medicine 9. SPONSORMONITORING AGENCY NAME(S) AND ADDRESS(ES) NUMBER 10. SPONSORMONITOR'S ACRONYM(S) 12. SIGNEBUTION / AVAILABILITY STATEMENT 10. SPONSORMONITOR'S ACRONYM(S) 13. SUPPLEMENTARY NOTES 11. SPONSORMONITOR'S REPORT 14. ABSTRACT The hypothesis being lested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late itsue morbidity posses a variant allele in the ATM gene compared with patients who do not suffer number of ere each genetic faither and idensity of the protein incoded by the ATM gene for each genetic faitheration identified and subsequence actural and complete DHPLC screening of the ATM gene for eadition induced late stap ordison conclonal sudic	1. REPORT DATE (L	DD-MM-YYYY)	2. REPORT TYPE		3. D	ATES COVERED (From - To)		
ATT Mutations and the Development of Severe Radiation-Induced Morbidity Image: Control of Contrel of Control of Control of Control of Control	01-07-2005		Annual		1 J	UI 2004 – 30 JUN 2005		
Following Radiutherapy for Breast Cancer b. GRATT MUMBER DAMD 17-02-1-0503 Sc. PROGRAM ELEMENT NUMBER S. AUTHOR(S) Barry S. Rosenstein, Ph.D. sd. PROJECT NUMBER E-Mail: b. CRAST NUMBER J. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) sd. PROJECT NUMBER Mount Sinal School of Medicine New York, NY 10029-6574 st. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) J. S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORMONTOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSORMONTOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who do not suffer these complications. An additional objective is to determine the functional Impact upon the protein encoded by the ATM gene for each genetic alteration identified and subsequent collular radiosensitivity. The specific alteration identified as ATM variant identi	ATM Mutations a	and the Development	of Severe Radiatio	on-Induced Morbidity	Ja.	CONTRACT NOMBER		
Instrume DAND17021-0503 Sc. PROGRAM ELEMENT NUMBER Barry S. Rosenstein, Ph.D. E-Mail: barry tosenstein@mssm.edu T. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai School of Medicine New York, NY 10029-6574 9. SPONSOR/MONITOR'S AGENCY NAME(S) AND ADDRESS(ES) Num Sinai School of Medicine New York, NY 10029-6574 9. SPONSOR/MONITOR'S AGENCY NAME(S) AND ADDRESS(ES) U. S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity posses a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each of this project are to (1) screen 50 breast cancer patients for ATM geneic alterations who developed radiation induced tas subcutaneous insue morbidity, (2) setablish a compared with patients who do not suffer these complications. An additional dosbesqueru collular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM geneic alterations with develope	Following Radiotherany for Breast Cancer				5b.	5b. GRANT NUMBER		
6. AUTHOR(§) 5C. PROGRAM ELEMENT NUMBER Barry S. Rosenstein, Ph.D. 5d. PROJECT NUMBER E-Mail: barry tosenstein@mssm.edu 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(§) AND ADDRESS(E\$) 5. PERFORMING ORGANIZATION REPORT NUMBER Mount Sinai School of Medicine 5. PERFORMING ORGANIZATION NAME(§) AND ADDRESS(E\$) 10. SPONSORING / MONITORING AGENCY NAME(§) AND ADDRESS(E\$) U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(\$) 11. SPONSOR/MONITOR'S ACRONYM(\$) 12. Stringution / AVAILABILITY STATEMENT Approved for Public Release: Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(\$) 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being lested in this project is that a greater proportion of patients who develop radiation-induced aubcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional dolpedtive is to determine the functional impact upon the protein encoded by the ATM gene for each cate leaders or followers likelius radiosensitivity. The specific aims of this project is to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced tas subsequent cellular radiosensitivity and normal activity of the protein produced tas subcuraneous late textent each ATM variant identified subcuraneous issue world as the perform functional studies using cells from patients without evidered for theorem to this late radiation reaction, and (3) perform functional studies using cells from patients without evidered is the protein produced by the	i onoring i ladio				DAMD17-02-1-0503			
6. AUTHOR(5) Barry S. Rosenstein, Ph.D. 54. PROJECT NUMBER E-Mail: barry rosenstein@mssm.edu 56. TASK NUMBER 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Mount Sinal School of Medicine New York, NY 10029-6574 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(5) 12. S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(5) 13. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR'S REPORT NUMBER(3) 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the AT/M gene compared with patients who develop radiation-induced absocutaneous late tissue morbidity possess a variant allele in the AT/M gene tile attrations who developed radiation induced late subcutaneous tissue morbidity (2) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced late subcutaneous table worbidity (2) screen 50 breast cancer patients for patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patient identified as ATM carriers to determine to what extent each ATM variant identified atfects radiosensitivity. The main activity of the protein produced by the ATM gene. 18. SUBJECT TEMMS No abstract provided. 11. LIMITATION OF ABSTRACT					5c.	PROGRAM ELEMENT NUMBER		
E-Mail: barry rosenstein@mssm.edu 5. TASK NUMBER F. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 6. PERFORMING ORGANIZATION REPORT Mount Sinal School of Medicine 8. PERFORMING ORGANIZATION REPORT New York, NY 10029-6574 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) sorcen 50 breast cancer patients for ATM genetic alteratified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene for additional subjects are performance of functional studies using cells from patients identified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene. 15. SUBJECT TEMMS 11. SUBJECT TEMMS	6. AUTHOR(S) Barry S. Rosens	tein Ph D	. <u>, , , , , , , , , , , , , , , , , , ,</u>		5d.	PROJECT NUMBER		
E-Mail: barry rosenstein@msm.edu 5f. WORK UNIT NUMBER 7_PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Mount Sinal School of Medicine 8. PERFORMING ORGANIZATION REPORT Number 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Material Command 11. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) T4. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the 47M gene compared with patients who do suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the 47M gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced by the ATM gene for each genetic alteration (2) porform functional subtuids using cells from patients dentified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene for additional subjects are genetic nearest and complete DHPLC screening of the ATM gene for additional subjects are dard protein levels and p53 phosphorylation by ATM. 15. SUBJECT TEMMS 17. LIMITATION OF ASTRACT 18. NUMBER (motive image) 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ASTRACT 19. ADME OF	Burry C. Robons				5e.	TASK NUMBER		
E-Mail: barry.rosensitein@mssm.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Num Sinai School of Medicine 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each genetic atteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced subcutaneous tasue morbidity, (2) estabilish a control group and screen 100 patients without evidence of the late radiation reaction, and (3) perform functional studies using collis from patients without evidence of the ATM gene for additional studies using collis from patients identified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene. The main accomplishments during the past year were acc			•		5f. V	WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Mount Sinai School of Medicine NUMBER New York, NY 10029-6574 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 12. S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(S) 13. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who doveloped radiation induced late subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who developed radiation induced late subcutaneous to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation reaction, and (3) perform functional studies using cells from patient identified at TM carriers to determine to what extent each ATM variant identified affects radiosensitivity. The main accomplishments during the past year were accrual and complete DHPLC Screening of the ATM gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS No abstract provided. 18. NUMBER include entry of PAGES 19b. TELEPHONE NUMBER include entry 19b. TELEPHONE NUMBER include entry <td>E-Mail: barry.ros</td> <td>senstein@mssm.edu</td> <th></th> <td></td> <td></td> <td></td>	E-Mail: barry.ros	senstein@mssm.edu						
Mount Sinal School of Medicine New York, NY 10029-6574 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being lested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the <i>ATM</i> gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the <i>ATM</i> gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for <i>ATM</i> genetic alterations who developed radiation induced late subcutaneous tissue morbidity. (2) establish a control group and screen 100 patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients identified as <i>ATM</i> carriers to determine to what extent each <i>ATM</i> variant identified affects radiosensitivity and normal activity of the protein produced by the <i>ATM</i> gene. The main accomplishments during the past year were accrual and complete DHPLC screening of the <i>ATM</i> gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS No abstract provided. 17. LIMITATIO	7. PERFORMING OI	RGANIZATION NAME(S)	AND ADDRESS(ES)		8. P	ERFORMING ORGANIZATION REPORT		
s. SPONSORING / MONITORING AGENCY NAME(3) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(5) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(5) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S ACRONYM(5) 12. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(S) Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation reaction, and (3) perform functional studies using cells from patients identified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS 17. LIMITATION of ABSTRACT 18. NUMBER of RESPONSIBLE PERSON of ABSTRACT 19. D. BASTRACT 0. THIS PAGE 19. TELEPHONE NUMBER (include area core) <td>Mount Sinai Sch New York, NY 1</td> <td>ool of Medicine 0029-6574</td> <th></th> <td></td> <td></td> <td></td>	Mount Sinai Sch New York, NY 1	ool of Medicine 0029-6574						
13. Strand and the one of the second and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the <i>ATM</i> gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the <i>ATM</i> gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for <i>ATM</i> genetic alterations who developed radiation induced late subcutaneous tissue morbidity, (2) establish a control group and screen 100 patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients identified at <i>TM</i> gene for accomplishments during the past year were accrual and complete DHPLC screening of the <i>ATM</i> gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS No abstract provided. 16. SECURITY CLASSIFICATION OF: U 17. LIMITATION U 18. NUMBER OF PAGES 19b. TELEPHONE NUMBER (include area code)				20/E0)	- 10			
Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced late subcutaneous tissue morbidity, (2) establish a control group and screen 100 patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients identified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene. The main accomplishments during the past year were accrual and complete DHPLC screening of the ATM gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS No abstract provided. 17. LIMITATION U 18. NUMBER 19b. TELEPHONE NUMBER (include area code)	U.S. Army Medic	al Research and Ma	teriel Command	53(23)	10.	SPONSOR MONTOR S ACRONINGS		
11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the ATM gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the ATM gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for ATM genetic alterations who developed radiation induced late subcutaneous tissue morbidity, (2) establish a control group and screen 100 patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients identified as ATM carriers to determine to what extent each ATM variant identified affects radiosensitivity and normal activity of the protein produced by the ATM gene. The main accomplishments during the past year were accrual and complete DHPLC screening of the ATM gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS No abstract provided. 17. LIMITATION U 18. NUMBER 19. NAME OF RESPONSIBLE PERSON OF ABSTRACT 16. SECURITY CLASSIFICATION OF: U U 17. LIMITATION U 18. NUMBER 12. 12. 12. 13. 14. 15. 15. 12. 14. 15. 15. 15. 15. 15. 16. 17. 17. 18. 17. 18. 17. 18. 17. 18. 18. 18. 18. 19. 19. 19. 19. 19. 19. 19. 19. 19. 19	Fort Detrick, Mar	yland 21702-5012						
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the <i>ATM</i> gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the <i>ATM</i> gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for <i>ATM</i> genetic alterations who developed radiation induced late subcutaneous tissue morbidity, (2) establish a control group and screen 100 patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients identified as <i>ATM</i> carriers to determine to what extent each <i>ATM</i> variant identified affects radiosensitivity and normal activity of the protein produced by the <i>ATM</i> gene. The main accomplishments during the past year were accrual and complete DHPLC screening of the <i>ATM</i> gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 15. SUBJECT TERMS No abstract provided. 17. LIMITATION of ABSTRACT 18. NUMBER of PAGES 19a. NAME OF RESPONSIBLE PERSON (0F PAGES 18. REPORT U U UU 12 19b. TELEPHONE NUMBER (include area code)					11.	SPONSOR/MONITOR'S REPORT NUMBER(S)		
14. ABSTRACT The hypothesis being tested in this project is that a greater proportion of patients who develop radiation-induced subcutaneous late tissue morbidity possess a variant allele in the <i>ATM</i> gene compared with patients who do not suffer these complications. An additional objective is to determine the functional impact upon the protein encoded by the <i>ATM</i> gene for each genetic alteration identified and subsequent cellular radiosensitivity. The specific aims of this project are to (1) screen 50 breast cancer patients for <i>ATM</i> genetic alterations who developed radiation induced late subcutaneous tissue morbidity, (2) establish a control group and screen 100 patients without evidence of this late radiation reaction, and (3) perform functional studies using cells from patients identified as <i>ATM</i> carriers to determine to what extent each <i>ATM</i> variant identified affects radiosensitivity and normal activity of the protein produced by the <i>ATM</i> gene. The main accomplishments during the past year were accrual and complete DHPLC screening of the <i>ATM</i> gene for additional subjects as well as the performance of functional studies with a series of patient derived cell lines to measure radiosensitivity, ATM protein levels and p53 phosphorylation by ATM. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON a. REPORT b. ABSTRACT c. THIS PAGE U 12	13. SUPPLEMENTA	RY NOTES	nion Unimited					
16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON a. REPORT b. ABSTRACT c. THIS PAGE U U 18. NUMBER OF PAGES 19b. TELEPHONE NUMBER (include area code)	14. ABSTRACT The subcutaneous la these complicating gene for each ge The specific aim radiation induced evidence of this carriers to deterr produced by the The main accom additional subject radiosensitivity, A	e hypothesis being te te tissue morbidity p ons. An additional ob enetic alteration iden s of this project are t d late subcutaneous late radiation reactio nine to what extent e <i>ATM</i> gene. uplishments during th ts as well as the per ATM protein levels a	ested in this project pssess a variant all jective is to determ ified and subseque o (1) screen 50 breat tissue morbidity, (2) n, and (3) perform f each <i>ATM</i> variant id e past year were act formance of function nd p53 phosphoryla	is that a greater prop ele in the <i>ATM</i> gene ine the functional im int cellular radiosens ast cancer patients for establish a control g unctional studies usi lentified affects radio ccrual and complete nal studies with a se ation by ATM.	portion of patie compared with pact upon the itivity. or <i>ATM</i> genetic group and scree ng cells from p sensitivity and DHPLC screen ries of patient	ents who develop radiation-induced n patients who do not suffer protein encoded by the <i>ATM</i> c alterations who developed een 100 patients without patients identified as <i>ATM</i> normal activity of the protein ning of the <i>ATM</i> gene for derived cell lines to measure		
a. REPORT U U U UU 12 a. REPORT b. ABSTRACT c. THIS PAGE U U U 12	16. SECURITY CLA	SSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON		
	a REPORT		C. THIS PAGE			19b. TELEPHONE NUMBER (include area		
	U	U		00	12	code)		

Table of Contents

Cover	1
SF 298	2
Introduction	3
Body	4
Key Research Accomplishments	11
Reportable Outcomes	11
Conclusions	11
References	12

INTRODUCTION

The majority of female breast cancer patients treated with breast conservation protocols consisting of limited surgery followed by adjuvant radiation therapy to the breast and surgical bed can develop tissue changes within the irradiated volume. These changes are both expected and temporary, and in most instances will resolve with conservative medical management. In contrast, there is a small subset of patients who manifest persistent or late subcutaneous tissue changes that can result in poor cosmesis and often painful sequelae. In some cases there are plausible explanations for such reactions that may include large breast size, excessive radiation dose-fractionation schedules, use of concurrent chemotherapy, and medical comorbidities such as collagen vascular diseases and diabetes. However, there exists an important subset of patients with no clear explanation for excessive post-treatment morbidity and the potential for a genetic basis must be considered. The purpose of this study is to investigate whether the *ATM* gene plays a role in enhanced radiation sensitivity in this population. This gene was selected because the protein it encodes plays a critical role

in the response of cells to radiation and the repair of radiation-induced damage. Furthermore, cells possessing a mutated copy of this gene are more radiosensitive than cells from individuals with a normal genotype. In addition, the results of a pilot study screening breast cancer patients are supportive of the hypothesis that patients who are carriers of an *ATM* mutation are more likely to develop late radiation-induced subcutaneous tissue complications.

The principal goal of this project is to determine whether women who inherit an altered copy of the *ATM* gene are more prone to the development of late radiation-induced morbidity. This will be accomplished through comprehensive screening of the *ATM* gene for germline variants. If a correlation is found between radiosensitivity and *ATM* genetic status, this would indicate that possession of an altered *ATM* gene results in susceptibility to subcutaneous tissue complications for breast cancer radiotherapy patients. In addition, a determination will be made as to the pathogenic consequences of each *ATM* variant through the use of functional studies that will examine the *ATM* protein in cells from patients who are carriers of an alteration in this gene. This project is innovative as it represents the first study to use the powerful DHPLC mutation screening technique to investigate the association between *ATM* heterozygosity and radiation-induced morbidity in the female breast cancer population. It is also the first study to examine whether there is a correlation between the presence of specific *ATM* genetic alterations, development of radiation-induced complications, and impairment of *ATM* protein function based upon cellular and molecular analyses.

Confirmation of this hypothesis will have important and direct implications upon patient care. It may suggest that all newly diagnosed female breast cancer patients considering breast conservation management should be tested for *ATM* heterozygosity using the relatively rapid and efficient mutation screening approach outlined in this proposal. Those women found to harbor an *ATM* variant may not be ideal candidates for standard breast conservation protocols and could possibly be better served by alternate treatment approaches such as modified radical mastectomy and breast reconstruction. Alternatively, these women may be ideal candidates for a dose reduction trial. A reduced total dose to the breast may result in equivalent local control rates as germline *ATM* gene alterations should be present in both tumor and normal cells and cause enhanced radiation sensitivity for both cell types. However, this remains to be tested. In either case, *ATM* mutation detection may help to prevent many women from experiencing the poor cosmetic and potentially painful side effects that can result from conventional breast radiotherapy in *ATM* carriers.

Body

Due to the substantial delay until April 30, 2003 from the HSRRB (Human Subjects Review Board) of the DOD for approval of the human subjects protocol and consent forms for this project, which was followed by an additional delay to obtain approval from both the Mount Sinai and NYU IRBs, subject accrual into this study could not be initiated until the beginning of the second year of this project. Because of this delay, the U.S. Army Medical Research Acquisition Activity was notified on June 1,

2005 that we will exercise the option for a 12-month no-cost extension of this grant to enable completion of the work in this project. This will result in a revised termination date for this project of June 30, 2006. This was done per the Assistance Agreement, section 4.C. - "The recipient may make a one-time "no-cost" extension to the expiration date of the award for a period up to 12 months. The recipient shall notify the grants officer, in writing, at least 10 days prior to the expiration date of the award."

During the past year, the screening of 125 subjects was completed which began during the first year of the project. The first result of note, as indicated in the Table 1, was the substantial difference, and virtually no overlap, between the *ATM* variants detected in African-Americans women compared with the putative genetic alterations that play an important role for breast cancer patients who are not African-American.

Table 1. COMPARISON OF AFRICAN-AMERICAN AND NON-AFRICAN-AMERICAN PATIENTS

ATM Variant	Non-African-American Number (%)	African-American Number (%)		
334G>A	0	1 (3)		
378T>A	0	4 (10)		
735C>T	1 (1)	0		
1176C>G	0	2 (5)		
2119T>C	1 (1)	0		
2362A>C	1 (1)	0		
2442C-A	1 (1)	0		
2572T>C	1 (1)	0		
4138C>T	0	2 (5)		
4258C>T	1 (1)	0		
4400A>G	0	1 (3)		
4578C-T	0	1 (3)		
5071A-C	1 (1)	0		
5557G>A	14 (16)	3 (8)		
5558A>T	2 (2)	0		
6088A>G	1 (1)	0		
6176C-T	1 (1)	0		
7397C>T	1 (1)	0		
IVS62+8A>C	3 (3)	0		
IVS5-7C>T	0	1 (3)		
IVS16-1G>A	1 (1)	0		

Separating the patients between difference grades of fibrosis, the following results were obtained for the 125 subjects screened;

58 patients –grade 0 fibrosis

67 patients – grade 1-4 fibrosis

77% (34/44) of patients found to possess an *ATM* genetic alteration displayed at least grade 1 fibrosis.

41% (33/81) of patients who did not harbor an *ATM* variant displayed at least grade 1 fibrosis.

p<0.001 (chi-square)

100 patients –grade 0-1 fibrosis

25 patients – grade 2-4 fibrosis

32% (14/44) of patients found to possess an *ATM* genetic alteration displayed grade 2-4 fibrosis.

14% (11/81) of patients who did not harbor an *ATM* variant displayed grade 2-4 fibrosis. p = 0.02 (chi-square)

115 patients –grade 0-2 fibrosis

10 patients – grade 3-4 fibrosis

14% (6/44) of patients found to possess an *ATM* genetic alteration displayed grade 3-4 fibrosis.

5% (4/81) of patients who did not harbor an *ATM* variant displayed grade 3-4 fibrosis. p = 0.172 (chi-square)

In addition, a substantial amount of the work in the past year focused upon performance of functional assays to determine the effect of *ATM* sequence variants on the function of the ATM protein. This research was accomplished using lymphoblastoid cell lines derived from EBV transformed lymphocytes obtained from subjects, all of whom were never diagnosed with breast cancer. This work was performed using five cell lines from subjects who were not found to possess an *ATM* variant and eight subjects who were identified with *ATM* variants. Of these eight patients, four developed adverse responses from the radiotherapy while the remainder did not. Cellular radiosensitivity was measured in each cell line. However, the experiments are not complete to measure ATM and p53 phosphorylation in all cell lines and an NC (not complete) is indicated in these cases.

For experiments in which p53 phosphorylation was measured, cells were irradiated with either 0 or 4 Gy of x-rays and incubated either 0.5 or 2 hr. The densitometric results for each time point were divided by the value in each experiment for unirradiated cells to normalize these results. Each irradiation was performed a total of three times. The mean values (with standard deviations) for wild type cells incubated either 0.5 or 2.0 hr were 1.8+2.0 or 3.1+2.5, respectively. The results for the cell lines possessing variants are shown in Table 2. In addition, ATM protein levels were measured in each cell line in three separate experiments and divided by the average value obtained for the five wild type ATM cell lines.

Table 2. Functional Assays of Lymphoblastoid Cells Derived from Subjects Possessing *ATM* Variants

<u>Cell Line</u>	Radio- s <u>ensitive</u> Yes/No	<u>Nucleo</u> e <u>tide</u>	-Chang	<u>e Amiı</u> <u>Acid</u> <u>Posit</u>	no <u>Sub-</u> <u>stitution</u> ion	<u>ATM</u> level	<u>p53p</u> <u>0.5 h</u>	<u>p53p</u> <u>2 hr</u>
MS01-07	No	4917 5557 5558	G>A G>A A>T	1639 1853 1853	P>P D>N D>V	NC	NC	NC
MS01-30	Yes	IVS5- 378 4578	7C>T T>A C>T	n/a 126 1526	n/a D>E P>P	NC	NC	NC
MS01-33	No	4138	C>T	1380	H>Y	1.11+0.55	5.06+4.37	5.37+2.99
MS01-37	Yes	378 1176 4138	T>A C>G C>T	126 392 1380	D>E G>G H>Y	1.59+0.16	2.06+1.21	1.99+1.20
MS01-39	Yes	5557 5558	G>A A>T	1853 1853	D>N D>V	1.29+0.89	1.35+0.98	0.68+0.38
MS01-45	No	5557	G>A	1853	D>N	0.39+0.04	NC	NC
MS01-51	Yes	IVS5- 378	7C>T T>A	n/a 126	n/a D>E	0.73+0.46	NC	NC
MS02-06	No	1254	A>G	418	Q>Q	1.06+0.18	0.87+0.24	0.90+0.38

The only instance of a statistically significant result was obtained was for MS01-45 which exhibited a significantly lower level of ATM protein. In addition, MS01-39 and MS02-06 displayed less p53 phosphorylation at 2 hours following irradiation compared with wild type cells.

The radiosensitivity of each cell line was also determined from the growth response of cells irradiated with either 0, 0.5, 1.0 or 2.0 Gy of X-rays by extrapolating the growth curve to the intercept at zero time. An example is shown for a 4 Gy dose to wild type cells and the dose response based upon each growth curve is then provided. One cell line, MS01-30, appeared to be moderately radiosensitive. The patient from whom these cells were derived exhibited an adverse radiotherapy response.



MS01-07

MS01-30









MS01-33



SURVIVING FRACTION

MS01-39

MS01-45





MS01-51



MS02-06



Key Research Accomplishments

- Accrual and complete DHPLC screening of the *ATM* gene in a total of 125 breast cancer patients who received standard radiotherapy.
- Measurement of ATM functional activity through performance of western blots to measure ATM protein levels and p53 ser-15 phosphorylation with a series of wild type and ATM variant cell lines.
- Determination of cellular radiosensitivity in five wild type and eight *ATM* variant cell lines derived from breast cancer patients treated with radiotherapy.

Reportable Outcomes

None

Conclusions

- From the initial results obtained during the past year it appears that possession of an *ATM* variant or the manifestation of clinical radiosensitivity was not routinely associated with an abrogation of ATM functional activity based upon either ATM protein levels, p53 phosphorylation or cellular radiosensitivity. If upon testing of additional cell lines during the final year of this project this result is maintained, this finding may suggest that although relatively small changes in the ATM protein could be sufficient to cause clinical radiosensitivity, they are not adequate to produce a measurable impact upon ATM function as measured in cellular assays
- The sequence variants possessed by African-American patients are distinctly different from those detected in non-African-Americans. Hence, it is critical to screen African-American patients to identify the genetic predictors of radiosensitivity in this population.
- Possession of ATM sequence variants is associated with the development of late skin fibrosis in breast cancer patients treated with a standard radiotherapy protocol. However, having an ATM alteration by itself may not be adequate to predict clinical radiosensitivity. Therefore, ATM could be just one of a battery of radiation response genes, whose inheritance in a variant form, is predictive for the development of adverse radiation effects.
- For the final year of this project, additional patients who exhibited grade 3 fibrosis will be screened. Functional assays will also be performed with additional patients who either did or did not exhibit clinical radiosensitivity.

References

~ .

None

Appendices

None